Literature DB >> 11799184

Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization.

Jin Kim1, Theodore Smith, Neeraja Idamakanti, Kathy Mulgrew, Michele Kaloss, Helen Kylefjord, Patricia C Ryan, Michael Kaleko, Susan C Stevenson.   

Abstract

Adenovirus binds to mammalian cells via interaction of fiber with the coxsackie-adenovirus receptor (CAR). Redirecting adenoviral vectors to enter target cells via new receptors has the advantage of increasing the efficiency of gene delivery and reducing nonspecific transduction of untargeted tissues. In an attempt to reach this goal, we have produced bifunctional molecules with soluble CAR (sCAR), which is the extracellular domain of CAR fused to peptide-targeting ligands. Two peptide-targeting ligands have been evaluated: a cyclic RGD peptide (cRGD) and the receptor-binding domain of apolipoprotein E (ApoE). Human diploid fibroblasts (HDF) are poorly transduced by adenovirus due to a lack of CAR on the surface. Addition of the sCAR-cRGD or sCAR-ApoE targeting protein to adenovirus redirected binding to the appropriate receptor on HDF. However, a large excess of the monomeric protein was needed for maximal transduction, indicating a suboptimal interaction. To improve interaction of sCAR with the fiber knob, an isoleucine GCN4 trimerization domain was introduced, and trimerization was verified by cross-linking analysis. Trimerized sCAR proteins were significantly better at interacting with fiber and inhibiting binding to HeLa cells. Trimeric sCAR proteins containing cRGD and ApoE were more efficient at transducing HDF in vitro than the monomeric proteins. In addition, the trimerized sCAR protein without targeting ligands efficiently blocked liver gene transfer in normal C57BL/6 mice. However, addition of either ligand failed to retarget the liver in vivo. One explanation may be the large complex size, which serves to decrease the bioavailability of the trimeric sCAR-adenovirus complexes. In summary, we have demonstrated that trimerization of sCAR proteins can significantly improve the potency of this targeting approach in altering vector tropism in vitro and allow the efficient blocking of liver gene transfer in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799184      PMCID: PMC135917          DOI: 10.1128/jvi.76.4.1892-1903.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.

Authors:  D A Einfeld; D E Brough; P W Roelvink; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector.

Authors:  P Reynolds; I Dmitriev; D Curiel
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

3.  Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR.

Authors:  G Santis; V Legrand; S S Hong; E Davison; I Kirby; J L Imler; R W Finberg; J M Bergelson; M Mehtali; P Boulanger
Journal:  J Gen Virol       Date:  1999-06       Impact factor: 3.891

4.  Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies.

Authors:  T J Wickham; D M Segal; P W Roelvink; M E Carrion; A Lizonova; G M Lee; I Kovesdi
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors.

Authors:  M A Printz; A M Gonzalez; M Cunningham; D L Gu; M Ong; G F Pierce; S L Aukerman
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

7.  Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein.

Authors:  I Kirby; E Davison; A J Beavil; C P Soh; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain.

Authors:  S C Stevenson; M Rollence; B White; L Weaver; A McClelland
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.

Authors:  M I Gorziglia; C Lapcevich; S Roy; Q Kang; M Kadan; V Wu; P Pechan; M Kaleko
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

10.  Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR.

Authors:  I Kirby; E Davison; A J Beavil; C P Soh; T J Wickham; P W Roelvink; I Kovesdi; B J Sutton; G Santis
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

View more
  14 in total

Review 1.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 3.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

4.  Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter.

Authors:  M H Verheije; T Würdinger; V W van Beusechem; C A M de Haan; W R Gerritsen; P J M Rottier
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.

Authors:  Birgit Dreier; Annemarie Honegger; Christian Hess; Gabriela Nagy-Davidescu; Peer R E Mittl; Markus G Grütter; Natalya Belousova; Galina Mikheeva; Victor Krasnykh; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

Review 6.  Chapter two--Adenovirus strategies for tissue-specific targeting.

Authors:  Matthew S Beatty; David T Curiel
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 7.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

8.  Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response.

Authors:  G Sailaja; H HogenEsch; A North; J Hays; S K Mittal
Journal:  Gene Ther       Date:  2002-12       Impact factor: 5.250

9.  Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Authors:  Hua-Jung Li; Maaike Everts; Masato Yamamoto; David T Curiel; Harvey R Herschman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  MicroPET imaging of Cre-loxP-mediated conditional activation of a herpes simplex virus type 1 thymidine kinase reporter gene.

Authors:  G Sundaresan; R Paulmurugan; F Berger; B Stiles; Y Nagayama; H Wu; S S Gambhir
Journal:  Gene Ther       Date:  2004-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.